Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1655-1659

  Drusano, G L ^a   D'Argenio, D Z ^b   Preston, S L ^a   Barone, C ^a   Symonds, W ^c   Lafon, S ^d   Rogers, M ^d   Prince, W ^c   Bye, A ^c   Bilello, J A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b University of Southern California ^*  (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SYSTEM ANALYSIS;

ANTI-HIV AGENTS; CARBAMATES; COMPUTER SIMULATION; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MONTE CARLO METHOD; SULFONAMIDES;

EID: 0034038099     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1655-1659.2000     Document Type: Article

References (9)

1. Drusano, G. L., J. A. Bilello, D. S. Stein, M. Nessly, A. Meibohm, E. A. Emini, P. Deutsch, J. Condra, J. Chodakewitz, and D. J. Holder. 1998. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J. Infect. Dis. 178:360-367.
2. Drusano, G. L., D. Z. D'Argenio, W. Symonds, P. A. Bilello. J. McDowell, B. Sadler, A. Bye, and J. A. Bilello. 1998. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob. Agents Chemother. 42:2153-2159.
3. Eraker, S. A., J. P. Kirscht, and M. H. Becker. 1984. Understanding and improving patient compliance. Ann. Intern. Med. 100:25K-268.
4. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev 47:331-385.
5. Kempf, D. J., R. A. Rode, Y. Xu, E. Sun, M. E. Heath-Chiozzi, J. Valdes, A. J. Japour, S. Danner, C. Boucher, A. Molla, and J. M. Leonard. 1998. The duration of viral suppression during protease inhibitortherapy for HIV-I infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12:F9-FI4.
6. McGee, K. 1999. Ask the pharmacist: simpler is not always better. Am. Druggist 2(Suppl.):25-26.
7. Schumitzky, A. 1991. Nonparametric EM algorithms for estimating prior distributions. Appl. Math. Comput. 45:141-157.
8. Wainberg, M. A., and G. Friedland. 1998. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977-1983.
9. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.